Edition:
India

Armata Pharmaceuticals Inc (ARMP.A)

ARMP.A on American Stock Exchange

3.36USD
17 Jul 2019
Change (% chg)

-- (--)
Prev Close
$3.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,156
52-wk High
$19.18
52-wk Low
$2.15

Latest Key Developments (Source: Significant Developments)

Corvesta Inc Reports 6.4% Passive Stake In Armata Pharmaceuticals
Tuesday, 21 May 2019 

May 21 (Reuters) - Armata Pharmaceuticals Inc ::CORVESTA INC REPORTS 6.4% PASSIVE STAKE IN ARMATA PHARMACEUTICALS INC AS OF MAY 9 - SEC FILING.  Full Article

Ampliphi Biosciences Qtrly Loss Per Share $0.11
Tuesday, 7 May 2019 

May 6 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AMPLIPHI BIOSCIENCES CORP QTRLY LOSS PER SHARE $0.11.AMPLIPHI BIOSCIENCES CORP - CASH AND CASH EQUIVALENTS AT MARCH 31, 2018 TOTALED $5.5 MILLION.AMPLIPHI BIOSCIENCES CORP - MANAGEMENT EXPECTS MERGER WITH C3J THERAPEUTICS INC WILL CLOSE IN MID-MAY 2019.  Full Article

Ampliphi Biosciences Corp - To r=Rise Number Of Authorized Shares Of Common Stock To 217 Mln Shares
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES CORP - TO INCREASE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 67 MILLION SHARES TO 217 MILLION SHARES.  Full Article

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES SUCCESSFULLY OPTIMIZES MANUFACTURING PROCESS AND SCALE UP FOR AB-SA01 CLINICAL DEVELOPMENT.AMPLIPHI BIOSCIENCES - WHOLLY OWNED GMP FACILITY NOW CAPABLE OF PRODUCING MATERIAL FOR OVER 100,000 DOSES FROM EACH DRUG SUBSTANCE BATCH OF AB-SA01.AMPLIPHI BIOSCIENCES CORP - INTENDS TO INITIATE S. AUREUS BACTEREMIA CLINICAL TRIAL IN 2019.  Full Article

AmpliPhi Biosciences Q2 Loss Per Share $0.19
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AMPLIPHI BIOSCIENCES CORP QTRLY LOSS PER SHARE $0.19.AMPLIPHI BIOSCIENCES CORP - CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2018 TOTALED $5.8 MILLION.  Full Article

AmpliPhi Biosciences Q1 Loss Per Share $0.24
Wednesday, 16 May 2018 

May 15 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AMPLIPHI BIOSCIENCES CORP - QTRLY LOSS PER SHARE $0.24.  Full Article

Ampliphi Biosciences Announces Pricing Of $4 Mln Public Offering Of Common Stock
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Ampliphi Biosciences Corp ::AMPLIPHI BIOSCIENCES CORP - ANNOUNCED PRICING OF PUBLIC OFFERING OF 4 MILLION COMMON SHARES AT $1.00 PER SHARE.AMPLIPHI BIOSCIENCES ANNOUNCES PRICING OF $4.0 MILLION PUBLIC OFFERING OF COMMON STOCK.  Full Article

Ampliphi Biosciences Announces Positive Interim Results For Single-Patient Expanded Access Program For AB-SA01 And AB-PA01
Thursday, 4 Jan 2018 

Jan 3 (Reuters) - Ampliphi Biosciences Corp ::AMPLIPHI BIOSCIENCES ANNOUNCES POSITIVE INTERIM RESULTS FOR SINGLE-PATIENT EXPANDED ACCESS PROGRAM UTILIZING AB-SA01 AND AB-PA01.AMPLIPHI BIOSCIENCES CORP - TREATMENT WAS WELL TOLERATED IN ALL PATIENTS, WITH OVER 500 DOSES ADMINISTERED INTRAVENOUSLY OR BY INHALATION.AMPLIPHI BIOSCIENCES CORP - SEVEN PATIENTS WITH SERIOUS INFECTIONS WERE TREATED WITH AB-SA01 OR AB-PA01, WITH 6 PATIENTS ACHIEVING TREATMENT SUCCESS.AMPLIPHI BIOSCIENCES CORP - EXPECTS TO CONTINUE ITS EXPANDED ACCESS CLINICAL STRATEGY IN 2018, REVIEW DATA WITH FDA IN MID-2018.AMPLIPHI BIOSCIENCES CORP - EXPECTS TO CONTINUE TO INITIATE A PHASE 2 OR REGISTRATIONAL CLINICAL PROGRAM POTENTIALLY AS EARLY AS SECOND HALF OF 2018.  Full Article

Ampliphi Biosciences Files For Offering Of Up To $10.0 Mln Of Common Stock
Friday, 15 Dec 2017 

Dec 14 (Reuters) - Ampliphi Biosciences Corp ::AMPLIPHI BIOSCIENCES CORP FILES FOR OFFERING OF UP TO $10.0 MILLION OF COMMON STOCK - SEC FILING.  Full Article

AmpliPhi Biosciences Says Engaged Ladenburg Thalmann & Co To Review Strategic Alternatives
Friday, 15 Dec 2017 

Dec 14 (Reuters) - AmpliPhi Biosciences Corp ::AMPLIPHI BIOSCIENCES PROVIDES CORPORATE AND STRATEGIC UPDATE.AMPLIPHI BIOSCIENCES - ENGAGED LADENBURG THALMANN & CO. INC. TO REVIEW STRATEGIC ALTERNATIVES.  Full Article